Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development - Wikidata - awgldk - TriplyDB

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

http://www.wikidata.org/entity/Q27485759

about

Mouse models of dengue virus infection for vaccine testing Dengue: defining protective versus pathologic immunity Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 Dengue Fever: Causes, Complications, and Vaccine Strategies Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine Mouse models to study dengue virus immunology and pathogenesis Dengue viruses - an overview Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1 High Genetic Stability of Dengue Virus Propagated in MRC-5 Cells as Compared to the Virus Propagated in Vero Cells Production and characterization of vaccines based on flaviviruses defective in replication Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2 A trans-Complementing Recombination Trap Demonstrates a Low Propensity of Flaviviruses for Intermolecular Recombination Characterization of Recombinant Dengue-2 Virus Derived from a Single Nucleotide Substitution in the 5′ Noncoding Region A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates Dengue research opportunities in the Americas Historical Perspectives on Flavivirus Research Issues related to recent dengue vaccine development.Dengue type 4 live-attenuated vaccine viruses passaged in vero cells affect genetic stability and dengue-induced hemorrhaging in mice Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.Dengue vaccines: recent developments, ongoing challenges and current candidates.Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines.Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.CD8+ T-cell Responses in Flavivirus-Naive Individuals Following Immunization with a Live-Attenuated Tetravalent Dengue Vaccine Candidate.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study Molecular determinants of plaque size as an indicator of dengue virus attenuation Single-dose vaccine against tick-borne encephalitis.Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge.A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.Animal models of dengue virus infection

P2860

Q24276139-09349EB7-C50F-435B-8602-C75119D62858 Q24609884-8B874327-296A-403A-B6F9-4CE98EC849D7 Q24805308-53A49BF5-F593-45A3-9BD1-8DF82041146F Q26700082-CFC8A1A9-DE46-472B-BB28-CE1A899E5D06 Q26782367-1B636753-C480-4136-9BC5-1A11423B3E7F Q27010151-E2D93530-058D-4E23-B42D-9707FBE1D00B Q27026302-4A0E9693-904F-4496-B412-E43B6D8963C1 Q27303669-54D8A26D-10D5-417C-9807-2E5C263E0733 Q27469474-AF6CDB2C-1B36-4DA9-A2B6-7F82160B200D Q27469831-2112EC50-19C5-49C2-ADFE-FEF608CF6616 Q27478075-C8D09DBE-3C41-433F-B495-09A526A3F578 Q27478162-CE985F8D-66D5-4DEF-820F-6E8362C45A34 Q27485473-44B6199B-4223-4461-A5F5-E00C9B3CEC45 Q27486374-EF5399CD-38E7-4952-8145-2F6DEB6654AE Q27487013-1E82C206-0AFE-4E4B-81CD-A20FA8166F1F Q27487375-063E3B49-E70D-4048-91EE-DD825C968D6A Q27487946-EA4454E9-A4AC-49F5-A37E-ABCC2AFF176F Q27490533-0BEFD9BD-6960-4267-95FE-5267191B42D1 Q27491304-B1579627-63B8-4F62-83DE-C298ACC457DE Q28241909-BFA32E9C-75AE-4D26-B684-F572ED6D66C0 Q28656204-2D0A156B-81B1-4206-BCF7-6B5B8196922B Q29994534-46D7B0BF-092B-4717-A086-C181F8AAC4E5 Q30395396-07305B62-8084-4DCC-A507-CD084F7E41A9 Q34066921-B74018D5-0CE1-4843-9312-FC0049E70009 Q34202440-FC7DDEE8-F755-4EB2-8B32-A95862F561FB Q34362322-F3DFDB47-2E6A-4D50-8B36-BF23826AE426 Q34367194-6FDC5600-15E1-4D6A-ACDC-E4FD7CE67F53 Q34759091-AE02AE5C-3F9F-4E3C-80D3-DD58CCE54231 Q34787775-A5E153DC-A0CF-4BD0-A571-526714C68386 Q35031833-E9FB0C0C-7EA8-4E24-9587-259E8064BD49 Q35269464-4F4D7435-EDDD-4C80-A0FE-3C018F95C2E2 Q36024479-EBB27C05-6DA4-4F5B-9545-A18F0298DAE4 Q36208591-3C4CC003-4B4C-4DEC-B730-23805EDEF6B8 Q36288109-C8D47253-F623-4FD9-8C0C-0D73A9CF594D Q36906525-7FFFC939-F676-4249-A49A-9D8557F6C762 Q37088625-FF65ED2C-E86C-453D-ACC3-F72D00C8FE72 Q37336555-D11D52AD-E91A-46D4-8357-E382C1A5B447 Q37336762-A8A05365-70AC-4A69-AF86-10FB85D649A4 Q37423499-7956282A-B476-48EB-AED8-6A9EF727C554 Q37987131-B3F6A39D-0CB8-4C13-9B0E-6666196575F3

P2860

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

http://www.wikidata.org/entity/Q27485759

description

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

article scientifique (publié 2003-11)

@fr

articolo scientifico (pubblicato il 2003-11)

@it

artigo científico (publicado na 2003-11)

@pt

artículu científicu espublizáu en 2003

@ast

im November 2003 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: November 2003)

@en

vedecký článok (publikovaný 2003-11)

@sk

vetenskaplig artikel (publicerad på 2003-11)

@sv

name

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@ast

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@en

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@nl

type

label

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@ast

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@en

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@nl

prefLabel

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@ast

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@en

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@nl

P1433

Q27485759-DDECD078-57AB-4E04-A04A-B8A12177C3B6

P1476

Q27485759-C66D201A-B668-4561-855E-6437BA109913

P2093

Q27485759-307FE8E9-4F09-456C-9984-724472FF8F80

Q27485759-3DD0AF73-670B-4D59-A662-321CF7775D23

Q27485759-53EEBF56-9A87-4D2E-9D7A-E5DAA16D6270

Q27485759-914AE8A6-A6AC-4F39-9538-E597B26B7F2B

Q27485759-BF908A4C-4B55-4104-A3B7-152E324AB11C

P2860

Q27485759-0B07469E-F451-41DE-B9F3-67746EF9A9EC

Q27485759-1A8AAAC6-4746-4789-9B00-49FCA6D72DD1

Q27485759-26711C97-B7C4-409F-BA8C-0325DA0B2C85

Q27485759-2752CC3F-8124-484E-B666-61C5FDCF640D

Q27485759-3253AEEC-F932-44AC-9928-F7A74BDEF240

Q27485759-326CA88F-FEA0-4779-B086-5196D2B55E4C

Q27485759-35777318-31C0-4466-8735-7CFFCC5E2290

Q27485759-3CC9B578-B051-430C-83D4-D9E0BF019336

Q27485759-3F079E0E-4A74-404F-9B0A-0A8093687FB4

Q27485759-3F372341-5D1F-48AF-98E3-B2F9CA34C3C8

P304

Q27485759-D7D6982C-3FE5-4BF3-924A-1D87A5027874

P31

Q27485759-BF988E94-8044-47A2-82B0-B36E53FEDEFE

P3181

Q27485759-9A5CE7C4-5FEB-42D4-8D4F-B616AF56409E

P356

Q27485759-CD25325E-030C-433C-8B1B-60EFD4DE2034

P433

Q27485759-1895A617-2EB1-4CD4-BFAE-098D8D80E3D3

P478

Q27485759-AA121151-3EFB-42E4-80DE-80095E537091

P50

Q27485759-FDFA0AD6-1C3D-4050-91FE-44607899FEDD

P577

Q27485759-E24C7035-1793-43A0-84AD-8E68859816CA

P5875

Q27485759-0734A890-3580-4910-911D-ED5BBF3469B1

P698

Q27485759-C9636DC0-62E7-431B-B5C8-5358D1614C8B

P921

Q27485759-07C37C66-D7BF-414E-ADCD-87A8D62C7E9A

P932

Q27485759-AD40E393-5841-4481-B8D2-864EB33A7FCF

P3181

P356

JVI.77.21.11436-11447.2003

P1433

Journal of Virology

P1476

Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development

@en

P2093

Claire Y-H Huang

http://www.w3.org/2001/XMLSchema#string

Kiyotaka R Tsuchiya

http://www.w3.org/2001/XMLSchema#string

Natth Bhamarapravati

http://www.w3.org/2001/XMLSchema#string

Richard M Kinney

http://www.w3.org/2001/XMLSchema#string

Siritorn Butrapet

http://www.w3.org/2001/XMLSchema#string

P2860

Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host

New mouse model for dengue virus vaccine testing

Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3

Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E

Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Yellow Fever Virus/Dengue-2 Virus and Yellow Fever Virus/Dengue-4 Virus Chimeras: Biological Characterization, Immunogenicity, and Protection against Dengue Encephalitis in the Mouse Model

Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge

Subgenomic replicons of the flavivirus Kunjin: construction and applications

P304

11436-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1434142

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/JVI.77.21.11436-11447.2003

http://www.w3.org/2001/XMLSchema#string

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

Duane J. Gubler

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9051618

http://www.w3.org/2001/XMLSchema#string

P698

14557629

http://www.w3.org/2001/XMLSchema#string

P921

P932

229366

http://www.w3.org/2001/XMLSchema#string